Login / Signup

Fertility-Sparing Management May Be Considered in Young Women with Uterine Sarcoma.

Szymon PiatekIwona SzymusikAnna Dańska-BidzińskaMariusz OłtarzewskiGabriela TrojanMariusz Bidzinski
Published in: Journal of clinical medicine (2022)
Uterine sarcomas occur very rarely in young women. Hysterectomy, which is a standard treatment, may not be acceptable for those patients, especially nulliparous women. Fertility-sparing management may be an alternative. The aim of the study was to assess fertility-sparing management in patients with uterine sarcoma. Eleven patients were eligible for the study. Histopathologic types of the tumor included: adenosarcoma (n = 3), low-grade endometrial stromal sarcoma ( n = 3), low-grade myofibroblastic sarcoma ( n = 1), leiomyosarcoma ( n = 1), leiomyosarcoma myxoides ( n = 1), rhabdomyosarcoma ( n = 1), high grade endometrial stromal sarcoma ( n = 1). The mean age of the patients at the time of diagnosis was 27.4 years (range: 17-35) and the average follow-up 61 months (range: 12-158). Six patients received adjuvant treatment: megestrol ( n = 5) and chemotherapy ( n = 1). Recurrence was diagnosed in five cases. Median time to recurrence was 35 months (range: 8-90). Three patients conceived spontaneously following treatment and gave at least one live birth. In total, five full-term pregnancies were recorded and five healthy children were born. Fertility-sparing management may be considered in some patients with uterine sarcoma; however, it may not be appropriate in high-grade endometrial stromal sarcoma. Patients with adenosarcoma may have a low chance of childbearing.
Keyphrases